Meet Our Leadership
A flexible, high-performance team is necessary in today’s changing healthcare environment. Our leadership team works together to design innovative strategies that leverage PRC technology, creating clinically actionable solutions.
Our team’s mission is to provide rapid, accurate actionable PCR solutions for infectious diseases and antimicrobial stewardship to every patient in America.
Executive Chairman & CEO
Martin
Price
Chief Financial Officer
Steve
Armond
Chief Growth & Strategy Officer
Michael
Bennett
Chief Compliance Officer
Stephanie
Bywater
Chief Commercial Officer
John
Moore
Chief Operating Officer
Guhan
Raghu
General Counsel
Kendra
Green Dias
Senior Vice President of
Laboratory & Clinical Strategy
Jay
Reddy, PHD
Executive Chairman & CEO
Martin
Price
Chief Financial Officer
Steve
Armond
Chief Growth & Strategy Officer
Michael
Bennett
Chief Compliance Officer
Stephanie
Bywater
Chief Commercial Officer
John
Moore
Chief Operating Officer
Guhan
Raghu
General Counsel
Kendra
Green Dias
Senior Vice President of
Laboratory & Clinical Strategy
Jay
Reddy, PHD
Executive Chairman & CEO
Martin
Price
Chief Financial Officer
Steve
Armond
Chief Growth & Strategy Officer
Michael
Bennett
Chief Compliance Officer
Stephanie
Bywater
Chief Commercial Officer
John
Moore
Chief Operating Officer
Guhan
Raghu
General Counsel
Kendra
Green Dias
Senior Vice President of
Laboratory & Clinical Strategy
Jay
Reddy, PHD
Meet
Our Advisory Board
Our advisors are extraordinary healthcare leaders representing public health policy, research, and clinical thought leadership. Their collective skills and industry expertise help to guide our executive team in their efforts to fuel ongoing growth and development.
Meet
Our Clinical Advisory Board
As the nation’s premier PCR-based infectious disease laboratory, we are committed to transforming diagnostics with custom solutions that provide rapid, clinically-actionable results to providers and their patients.
Our Clinical Advisory Board, composed of leading infectious disease (ID) and antimicrobial resistance (AMR) experts, guides the development of new tests and menus, advocates for guideline-based molecular testing, and facilitates clinical trials. Insights from the Board not only advance our PCR testing program, but also demonstrate its utility in improving ID patient outcomes and combating AMR.